Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
Joao Pedro FerreiraSubodh VermaDavid FitchettAnne Pernille OfstadSabine LauerIsabella ZwienerJyothis GeorgeChristoph WannerBernard ZinmanSilvio E InzucchiPublished in: Cardiovascular diabetology (2020)
A large proportion of the EMPA-REG OUTCOME population fulfills the criteria for MetS. Those with MetS had increased risk of adverse cardio-renal outcomes. Compared with placebo, empagliflozin improved cardio-renal outcomes in patients with and without MetS. Trial registration Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01131676.